Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis
James Bundred(University of Leeds), Nigel Bundred(Manchester Academic Health Science Centre), Jacqui Gath(Humber Teaching NHS Foundation Trust), Bernd Holleczek(Krebsregister Saarland), Jane E. Dahlstrom(Australian National University), Ramsey Cutress(University of Southampton), Beth Stuart(Queen Mary University of London), David Dodwell(University of Oxford), Sarah Michael(University of Manchester), Kerri Beckmann(The University of Adelaide)
Cited by 130
Related Papers
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Stillbirths: recall to action in high-income countries
|The Lancet|2016|689
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
|The Lancet Oncology|2018|501